Elenbecestat

SKU: orb1309713

Description

Elenbecestat (E2609) is an orally bioavailable, brain-penetrant BACE1 inhibitor for Alzheimer's disease research. It has been investigated in preclinical and clinical studies for its ability to reduce amyloid-beta production in both cellular assays and animal models.

Research Area

Neuroscience

Key Properties

• CAS Number: 1388651-30-6
• MW: 437.44
• Purity: 99.95% (May vary between batches)
• Formula: C₁₉H₁₈F₃N₅O₂S
• SMILES: [H][C@]12CSC(N)=N[C@]1(CO[C@@H]2C)c1cc(NC(=O)c2cnc(cn2)C(F)F)ccc1F
• Target: BACE,Beta-Secretase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (11.43 mM);DMSO:250 mg/mL (571.51 mM)

Bioactivity

• In Vivo:
  E2609 (0.3-30 mg/kg; p.o.) potently inhibits Ab1-40 and Ab1-42 production in the plasma and CSF of non-human primates.E2609 displays the plasma half-life of 12-16 hours after once daily dosing.
  Read more...
• In Vitro:
  E2609 has been shown to reduce Ab production in the plasma, brain, and cerebrospinal fluid (CSF) of rodents.E2609 is a potent BACE1 inhibitor with an IC50 of ~7 nmol/L in cell-based assay.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

βSecretase, β-Secretase, E2609, E-2609, E 2609, Alzheimer's disease, bSecretase, b-Secretase, BetaSecretase, Beta-secretase, BACE, BACE1, BACE-1, inhibit, Inhibitor, Elenbecestat

Compound Identifiers

PubChem CID

57827330